Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice

Current Medical Research and Opinion

Volumn 26, Issue 7, 2010, Pages 1637-1645

  Huang, Xingyue ^a   Gu, Ning Yan ^b   Fox, Kathleen M ^c   Harrison, David J ^a   Globe, Denise ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

Author keywords

Claims analysis; Dose escalation; Methods; Rheumatoid arthritis; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; ETANERCEPT; ANTIRHEUMATIC AGENT; HORMONE ANTAGONIST; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OUTCOME ASSESSMENT; PRESCRIPTION; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; UNITED STATES; ALGORITHM; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DOSE CALCULATION; DOSE RESPONSE; EVALUATION STUDY; MIDDLE AGED; PROFESSIONAL PRACTICE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; HORMONE ANTAGONISTS; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROFESSIONAL PRACTICE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953571315     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.483127     Document Type: Article

References (18)

1. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl. 1):i2-29
2. Enbrel (etanercept) Prescribing Information. Thousand Oaks, CA: Immunex Corporation, 2007
3. Humira (adalimumab) Prescribing Information. North Chicago, IL: Abbott Laboratories, 2007
4. Remicade (infliximab) Prescribing Information. Malvern, PA: Centocor, Inc., 2006
5. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-1740
6. Sidiropoulos P, Boumpas D. Differential drug resistance to anti-tumor necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:701-703
7. Haraoui B, Cameron L, Ouellet M, et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-36
8. Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, et al. Dose escalation of the anti-TNF-a agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007;46:529-532
9. Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-2025
10. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53
11. Abarca J, Malone DC, Armstrong EP, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538-542
12. Gilbert Jr TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
13. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-430
14. Ollendorf DA, Massrotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005; 11:383-393
15. Harley CR, Frytak R, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etancercept, or methotrexate. Am J Manag Care 2003;9(Suppl. 6):136-143
16. Chapter 8, Cohort Studies. In: Greenberg RS, Daniels S, Flanders WD, Eley JW, Boring JR (eds.) Medical Epidemiology. Norwalk, CT: Appleton & Lange, 1993:89-132
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-383
18. SAS Institute Inc., Cary, NC, USA. SAS version 9.1.3